LY2608204 is a potent used to treat type 2 diabetes. In a clinical trial, a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | Male Wistar rats at a weight of 225-250 g |
| Formulation | LY2608204 is suspended in a 1:1 mixture of solutol/ethanol in a bath sonicator (10% of total volume). The obtained suspension is then diluted with 9 volumes of 10% aqueous solutol solution. |
| Dosages | 1, 3, 6, 10, 20 and 30 mg/kg |
| Administration | Orally, rats are given a 2 g/kg oral glucose bolus 2 hours after LY2608204 administration. |
| Molecular Weight | 559.81 |
| Formula | C28H37N3O3S3 |
| CAS Number | 1234703-40-2 |
| Form | Solid |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Glucokinase (GK) Products |
|---|
| AZD1092
AZD1092 is an orally active glucokinase (GK) activator with an EC50 value of 0.03 μM. |
| GKM-001
GKM-001 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes. |
| TMG-123
TMG-123 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes. |
| PB-201
PB-201 is a glucokinase activator (GKA) that can be used in studies related to type 2 diabetes. |
| MK-0941 free base
MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
